EA200601392A1 - METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIPODYSTROPHY - Google Patents
METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIPODYSTROPHYInfo
- Publication number
- EA200601392A1 EA200601392A1 EA200601392A EA200601392A EA200601392A1 EA 200601392 A1 EA200601392 A1 EA 200601392A1 EA 200601392 A EA200601392 A EA 200601392A EA 200601392 A EA200601392 A EA 200601392A EA 200601392 A1 EA200601392 A1 EA 200601392A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lipodystrophy
- methods
- treatment
- compositions
- hiv
- Prior art date
Links
- 206010049287 Lipodystrophy acquired Diseases 0.000 title abstract 4
- 208000006132 lipodystrophy Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Настоящее изобретение относится к способам и композициям для лечения липодистрофии. Способы предусматривают лечение липодистрофии как у ВИЧ, так и у не-ВИЧ пациентов. Более конкретно, способы относятся к комбинированной терапии, в которой используют гормон роста и статины для осуществления лечения липодистрофии.The present invention relates to methods and compositions for the treatment of lipodystrophy. The methods include the treatment of lipodystrophy in both HIV and non-HIV patients. More specifically, the methods relate to combination therapy in which growth hormone and statins are used to treat lipodystrophy.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54020404P | 2004-01-29 | 2004-01-29 | |
| US54336604P | 2004-02-10 | 2004-02-10 | |
| PCT/EP2005/000758 WO2005074916A1 (en) | 2004-01-29 | 2005-01-26 | Methods and compositions for the treatment of lipodystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200601392A1 true EA200601392A1 (en) | 2006-12-29 |
Family
ID=34841102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200601392A EA200601392A1 (en) | 2004-01-29 | 2005-01-26 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIPODYSTROPHY |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1722778A1 (en) |
| JP (1) | JP2007519669A (en) |
| KR (1) | KR20060127977A (en) |
| AU (1) | AU2005210093A1 (en) |
| BR (1) | BRPI0507302A (en) |
| CA (1) | CA2552404A1 (en) |
| EA (1) | EA200601392A1 (en) |
| IL (1) | IL176762A0 (en) |
| NO (1) | NO20063279L (en) |
| WO (1) | WO2005074916A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903312B1 (en) | 2006-07-05 | 2008-09-26 | Univ Aix Marseille Ii | USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT |
| CN102698276B (en) * | 2008-01-03 | 2014-12-10 | 艾克斯-马赛大学 | Bitherapy and tritherapy used for treating an HIV-positive patient |
| WO2010121352A1 (en) * | 2009-04-20 | 2010-10-28 | Theratechnologies Inc. | Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy |
| JP6712230B2 (en) * | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | Methods for treating metabolic disorders associated with lipodystrophy and defective insulin production or defective insulin signaling |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9803623D0 (en) * | 1998-10-22 | 1998-10-22 | Sahltech Ab | New therapeutic application |
-
2005
- 2005-01-26 KR KR1020067016376A patent/KR20060127977A/en not_active Application Discontinuation
- 2005-01-26 AU AU2005210093A patent/AU2005210093A1/en not_active Abandoned
- 2005-01-26 EP EP05707019A patent/EP1722778A1/en not_active Withdrawn
- 2005-01-26 JP JP2006550092A patent/JP2007519669A/en active Pending
- 2005-01-26 CA CA002552404A patent/CA2552404A1/en not_active Abandoned
- 2005-01-26 WO PCT/EP2005/000758 patent/WO2005074916A1/en active Application Filing
- 2005-01-26 EA EA200601392A patent/EA200601392A1/en unknown
- 2005-01-26 BR BRPI0507302-2A patent/BRPI0507302A/en not_active IP Right Cessation
-
2006
- 2006-07-10 IL IL176762A patent/IL176762A0/en unknown
- 2006-07-14 NO NO20063279A patent/NO20063279L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20063279L (en) | 2006-09-19 |
| JP2007519669A (en) | 2007-07-19 |
| CA2552404A1 (en) | 2005-08-18 |
| KR20060127977A (en) | 2006-12-13 |
| BRPI0507302A (en) | 2007-06-26 |
| IL176762A0 (en) | 2006-10-31 |
| AU2005210093A1 (en) | 2005-08-18 |
| EP1722778A1 (en) | 2006-11-22 |
| WO2005074916A1 (en) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005026866D1 (en) | USE OF THREE-DIMENSIONAL CULTURED TISSUE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE | |
| ATE489957T1 (en) | AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| EA200700175A1 (en) | COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY DISEASES | |
| NO20064547L (en) | Methods for treating HIV infection | |
| MX2007011545A (en) | Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors. | |
| EA201390772A1 (en) | NEW SALTS AND POLYMORPHIC FORMS OF AFATINIBA | |
| MA33806B1 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
| EA200700225A1 (en) | TETRAPTIDE ANALOGUES | |
| EA200870569A1 (en) | CONNECTIONS AND METHODS OF FXR MODULATION | |
| EA200601776A1 (en) | METADONIC COMPOSITIONS OF LOCAL ACTION AND METHODS OF THEIR APPLICATION | |
| EA201000914A1 (en) | NEW THERAPEUTIC APPROACHES IN THE TREATMENT OF SMT AND RELATED DISORDERS | |
| EA200901490A1 (en) | CHEMICAL COMPOUNDS | |
| MX349188B (en) | Sns-595 and methods of using the same. | |
| EA200900802A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASES | |
| MX346450B (en) | Compositions and methods for treatment of celiac disease. | |
| BRPI0508390B8 (en) | use of an anti-ngf antagonist antibody, as well as kit and pharmaceutical composition for the treatment of bone cancer pain | |
| NO20092637L (en) | Methods of treatment | |
| EA200970747A1 (en) | ACTIVIN-ACTRIIA ANTAGONISTS AND APPLICATION TO STIMULATE BONE GROWTH IN CANCER PATIENTS | |
| EA200600078A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID DISEASES | |
| ATE495739T1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING LEVODOPA AND CARBIDOPA | |
| EA201290356A1 (en) | COMPOSITIONS FOR THE TREATMENT OF CHESTNUTS AND VOMITS OF CENTRAL ORIGIN | |
| EA201001749A1 (en) | METHOD OF TREATMENT OF DIFFERENTIATED ARTHRITIS | |
| EA201300421A1 (en) | COMBINED THERAPY FOR THE TREATMENT OF HCV INFECTION | |
| EA201400423A1 (en) | PHARMACEUTICAL PREPARATIONS AND THEIR APPLICATION IN THE TREATMENT OF SEXUAL DYSFUNCTION IN WOMEN | |
| ATE555108T1 (en) | POLYAMIDES FOR THE TREATMENT OF HUMAN PAPILLOMA VIRUS |